Others

Impurity Atenolol EP Impurity A
Applications 4-(Hydroxyphenyl)acetamide (Atenolol EP Impurity A) is used as an intermediate for the synthesis of Atenolol (A790075) and various other organic compounds and pharmaceuticals. It is a process impurity for Atenolol (A790075)
References Inkum, R., et al.: Maejo Int. J. Sci. Tech., 6, 372 (2012); Pai, N.R., et al.: J. Chem. Pharma. Rsch., 4, 375 (2012); Moon, J.T., et al.: Bio-org. Medn. Chem., 20, 734 (2012);

Applications Methyl Ethanesulfonate is a sulfonic acid ester that is transparent at around 157 nm region, and is used in DFT calculations of vacuum-UV spectra in order to design the vinyl alkylsulfonate polymers for vacuum-UV photoresist applications.
References Fujigaya, T., et al.: J. Photopolym. Sci. Tec., 15, 643 (2002);

Applications 2-[2-(2,2,2-Trifluoroethoxy)phenoxy]ethyl Methanesulfonate is an intermediate of Silodosin (S465000) which is an α1a-adrenoceptor antagonist and used in the treatment of benign prostatic hypertophy.
References Francesco, C., et al.: Eur. J. Org. Chem., 27, 6011 (2015)

Applications The main metabolite of Entacapone and Tolcapone.
References Mannisto, P., et al.: Prog. Drug Res., 39, 291(1992), Nishi, H., et al.: J. Pharm. Biomed. Anal., 11, 1277 (1993), Wikberg, T., et al.: Eur. J. Drug Metab. Pharmacokinet., 18, 359 (1993),

Applications Cyclopropanecarboxylic Acid is used as a reagent in the synthesis of substituted 4-(thiophen-2-ylmethyl)-2H-phthalazin-1-ones as potent PARP-1 inhibitors. Also used as a reagent in the synthesis of 2-alkyloxazoles as potent and selective PI4KIIIβ inhibitors demonstrating inhibition of HCV replication.
Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package
References Wang, L., et al.: Bioorg. Med. Chem. Lett., 24, 3739 (2014); Keaney, E.P., et al.: Bioorg. Med. Chem. Lett., 24, 3714 (2014)

Applications Antitumor agent. A potent inhibitor of dihydropyrimidine dehydrogenase (DPD).
References Shirasaka, T., et al.: Cancer Res., 56, 2602 (1996), Patt, Y., et al.: J. Clin. Oncol., 22, 271 (2004), Shirao, K., et al.: Cancer, 100, 2355 (2004), Kelly, H., et al.: J. Clin. Oncol., 23, 4553 (2005),